Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: LSE
Sector: Pharmaceuticals
Epic: ATD
News: Latest news
Web Site: Asterand
Other Articles: 08-07-201014-06-201014-06-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 02, 11:00Baobab Resources identifies distinct ore domain at Tete’s South Zone

Baobab MD Ben James said the latest drilling results from the Tete project's South Zone characterise a distinct, higher mass recovery, ore domain.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Thursday September 02, 08:15Indonesia edges closer toward uranium mining and nuclear power

After nearly five decades of national debate on the issue, Indonesia's central government may finally be ready to develop a national nuclear policy, which may lead to domestic uranium mining.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Wednesday September 01, 01:25Green Dragon Gas reports significant growth as China’s thirst for energy continues

China's thirst for energy resources has continued with an increased focus on domestic supplies of gas, Green Dragon Gas chairman Randeep Grewal said today. In the company's interim results, [...]

FULL ARTICLE ►
Asterand

Asterand

Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Their mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success.

CLICK HERE FOR FULL ANLAYSIS OF ASTERAND
Monday, November 23, 2009

Asterand and Bristol-Myers Squibb extend compound profiling collaboration

company news image

Supplier of human tissue and human tissue-based services Asterand (AIM: ATD) has announced the extension of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to its products and services for up to three years, focusing on its PhaseZERO drug discovery services and XpressBANK of human tissue and clinical samples.


Under the terms of the extended collaboration agreement, Asterand will continue to undertake a range of PhaseZERO studies for Bristol-Myers Squibb in compound profiling and target validation. Bristol-Myers will also gain access to XpressBANK of human tissue, bio-fluid and cell lines for the continued validation of drug targets and will also utilize Asterand’s ProCURE custom clinical sample collection service.


PhaseZERO studies include gene and protein expression profiling and cell-based pharmacology assays.


“This decision by Bristol-Myers Squibb is an important validation of Asterand's products and services...we are delighted that Bristol-Myers Squibb has renewed our collaboration and our team looks forward to continuing to support their target validation and compound optimisation programmes,” said Chief Executive of Asterand Martyn Coombs.


The company provides human based solutions for decision marking during the development of medicines. Asterand’s customers incorporate human tissue-based models at all stages of development from target identification to pre-clinical research.


Asterand reported revenues of £9.1 Million for the nine months to 30 September, up from £8 million for the equivalent period of the previous year. The cash resource stood at £5.2 million.


Shares in Asterand rose 2.5% in London on the news.

AddThis Feed Button
Register here to be notified of future Asterand articles.

Other Asterand news

More news ►

Investors interested in Asterand recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.